ChemicalBook > Product Catalog >API >Circulatory system drugs >Antihypertensive drugs >Sorafenib tosylate

Sorafenib tosylate

Sorafenib tosylate Suppliers list
Company Name: Capot Chemical Co.,Ltd.
Tel: +86 (0)571-855 867 18
Email: sales@capotchem.com
Products Intro: Product Name:Sorafenib Tosylate
CAS:475207-59-1
Purity:98%(Min,HPLC) Package:100g;1kg;5kg,10kg,25kg,50kg
Company Name: Beijing Cooperate Pharmaceutical Co.,Ltd.
Tel: +86-10-60279497 +86(0)15646567669
Email: sales01@cooperate-pharm.com
Products Intro: Product Name:Sorafenib tosylate
CAS:475207-59-1
Purity:98% Package:100G;1KG;5KG;10KG;25KG;50KG;100KG
Company Name: Shenzhen Sendi Biotechnology Co.Ltd.
Tel: 0755-23311925 18102838259
Email: Abel@chembj.com
Products Intro: Product Name:Sorafenib tosylate
CAS:475207-59-1
Purity:99% Package:5720/KG
Company Name: Frapp's ChemicalNFTZ Co., Ltd.
Tel: +86 (576) 8169-6106
Email: sales@frappschem.com
Products Intro: Product Name:Sorafenib tosylate
CAS:475207-59-1
Company Name: Dragon Fly INDUSTRY INT'L CO  Gold
Tel:15065329263
Email:info@goldenpromiseindustry.com
Products Intro:Product Name:Sorafenib tosylate
CAS:4750207-59-1
Purity:99.00%
Sorafenib tosylate Basic information
Indications and Usage Mechanisms of Action Clinical Research Adverse reactions
Product Name:Sorafenib tosylate
Synonyms:SORAFENIB TOSYLATE;Sorafenib & its intermediates;Sorafinib mesylate;4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide monomethanesulfonate;Sorafenib Tosylate(Bay 43-9006,Nexavar);2-PyridinecarboxaMide, 4-[4-[[[[4-chloro-3-(trifluoroMethyl)phenyl]aMino]carbonyl]aMino]phenoxy]-N-Methyl-, 4-Methylbenzenesulfonate;Sorafenib Tosylate (Nexavar);Sorafenib (Nexavar)
CAS:475207-59-1
MF:C21H16ClF3N4O3.C7H8SO3
MW:637.03
EINECS:
Product Categories:Bay 43-9006;Inhibitors;MAPK
Mol File:Mol File
Sorafenib tosylate Structure
Sorafenib tosylate Chemical Properties
CAS DataBase Reference475207-59-1(CAS DataBase Reference)
Safety Information
Risk Statements 36/37/38
Safety Statements 28-26
MSDS Information
Sorafenib tosylate Usage And Synthesis
Indications and UsageSorafenib tosylate is a new type of multi-target antitumor drug, was developed by the German Bayer Pharmaceuticals, and displayed expansive antitumor activity in preclinical animal tests. Sorafenib tosylate is mainly used in advanced liver cancer treatment and is well tolerated.
Mechanisms of ActionSorafenib tosylate can simultaneously affect tumor cells and tumor blood vessels. It has a double antitumor effect: it can block the cell signal transduction pathways mediated by RAF/MEK/ERK to directly inhibit tumor cell growth, while also inhibiting VEGF and platelet derived growth factors (PDGF) receptors to prevent the formation of new tumor blood vessels, thus indirectly inhibiting tumor cell growth.
Clinical ResearchIn a stage three randomized clinical study of American and European treatments for advanced kidney cancer, 903 cases advanced kidney patients who had experienced one unsuccessful systematic treatment (biological immunity or chemotherapy) were randomly split into two groups. One group received sorafenib tosylate, while the other received a placebo. Mid-term analysis found already 222 deaths and the objective efficacy of the two groups to be 10% and 2%, while 74% and 53% of patients had stabilized conditions. The sorafenib tosylate group’s survival period was longer than that of the placebo group, with the risk ratio as 0.72. However, this different does not have statistical significance, as this is only a mid-term analysis, and final analysis after treatment will yield the correct survival period comparison.
602 advanced liver cancer patients selected from the USA, Europe, Australia, and other countries and areas, who did not receive systematic treatment, were included in a study. Results showed that compared to the placebo, taking sorafenib tosylate could extend their total survival period of patients with late stage or primary liver cancer by about 44% and their extend disease progression period by about 73%.
Adverse reactionsManageable diarrhea, rashes, fatigue, hand-foot syndrome, hypertension, alopecia, nausea, vomiting, and loss of appetite.
UsesSorafenib Tosylate (Bay 43-9006, Nexavar) is a small molecular inhibitor of VEGFR, PDGFR, c-Raf and B-Raf with IC50s of 18 nM, 10 nM, 3 nM and 15 nM, respectively.
UsesSorafenib Tosylate (Bay 43-9006) is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively
UsesAn inhibitor of Flk-1 (VEGFR), PDGFR and Raf kinases.
Sorafenib tosylate Preparation Products And Raw materials
Tag:Sorafenib tosylate(475207-59-1) Related Product Information
Bortezomib Dasatinib Unii-33Y9anm545 Sunitinib Malate Ibrutinib N-(3-(5-(4-Chlorophenyl)-1H-pyrrolo[2,3-B]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonaMide Sorafenib tosylate Formamide p-Toluenesulfonic acid 4-Methoxyphenylacetone Sorafenib tosylate 4-CHLOROBENZOYLACETONITRILE CHLOANTRANILIPROLE Benzamide Diphenyldimethoxysilane N,N-Dimethylformamide